{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:43:22Z","timestamp":1793882602259,"version":"4.7.0"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["LD2023017\u3001LD2023010 LD2023019"],"award-info":[{"award-number":["LD2023017\u3001LD2023010 LD2023019"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MS-271"],"award-info":[{"award-number":["2024-MS-271"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer (GC) is one of the primary contributors to cancer-related mortality on a global scale. It holds a position within the top five most prevalent malignancies both in terms of occurrence and fatality rates. Immunotherapy, as a breakthrough cancer treatment, brings new hope for GC patients. Various biomarkers, such as the expression of programmed death ligand-1 (PD-L1), the microsatellite instability (MSI) status, tumor mutational burden (TMB), and Epstein\u2013Barr virus (EBV) infection, demonstrate potential to predict the effectiveness of immunotherapy in treating GC. Nevertheless, each biomarker has its own limitations, which leads to a significant portion of patients continue to be unresponsive to immunotherapy. With the understanding of the tumor immune microenvironment (TIME), genome sequencing technology, and recent advances in molecular biology, new molecular markers, such as POLE\/POLD1mutations, circulating tumor DNA, intestinal flora, lymphocyte activation gene 3 (LAG-3), and lipid metabolism have emerged. This review aims to consolidate clinical evidence to offer a thorough comprehension of the existing and emerging biomarkers. We discuss the mechanisms, prospects of application, and limitations of each biomarker. We anticipate that this review will open avenues for fresh perspectives in the investigation of GC immunotherapy biomarkers and promote the precise choice of treatment modalities for gastric cancer patients, thereby advancing precision immuno-oncology endeavors.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1599908","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:10:56Z","timestamp":1747195856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Fujing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhuo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008243606668","article-title":"Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer","volume":"8","author":"Glimelius","year":"1997","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.05.015","article-title":"Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care","volume":"86","author":"Petricevic","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1756284820948773","DOI":"10.1177\/1756284820948773","article-title":"Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers","volume":"13","author":"Eso","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.3390\/cancers14246150","article-title":"Repurposing of commercially existing molecular target therapies to boost the clinical efficacy of immune checkpoint blockade","volume":"14","author":"Sinha","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01067","article-title":"PD-L1 under regulation of miR-429 influences the sensitivity of gastric cancer cells to TRAIL by binding of EGFR","volume":"10","author":"Lv","year":"2020","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III checkMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02898-8","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1674","article-title":"Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial","volume":"14","author":"Zhao","year":"2024","journal-title":"Clin Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2020.02.002","article-title":"Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric\/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study","volume":"129","author":"Kawazoe","year":"2020","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927781","article-title":"Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15462","article-title":"Phase IIb study of pembrolizumab combined with S-1 +\u2009oxaliplatin or S-1 +\u2009cisplatin as first-line chemotherapy for gastric cancer","volume":"113","author":"Yamaguchi","year":"2022","journal-title":"Cancer Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4423","article-title":"Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma","volume":"9","author":"Manji","year":"2023","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13690","article-title":"Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma","volume":"11","author":"Qiu","year":"2020","journal-title":"Thorac Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.959295","article-title":"Neoadjuvant tislelizumab and tegafur\/gimeracil\/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.554040","article-title":"Case report: neoadjuvant PD-1 blockade plus concurrent chemoradiotherapy in unresectable locally advanced gastric cancer patients","volume":"10","author":"Wei","year":"2020","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2135819","DOI":"10.1080\/2162402x.2022.2135819","article-title":"Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer","volume":"11","author":"Tang","year":"2022","journal-title":"Oncoimmunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152448","article-title":"Programmed cell death-1 polymorphisms decrease the cancer risk: A meta-analysis involving twelve case-control studies","volume":"11","author":"Dong","year":"2016","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45090481","article-title":"Safety and efficacy of neoadjuvant chemoimmunotherapy in gastric cancer patients with a PD-L1 positive status: A case report","volume":"45","author":"Avgustinovich","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13046-019-1148-5","article-title":"Autophagy inhibition enhances PD-L1 expression in gastric cancer","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29464","article-title":"GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy","volume":"235","author":"Booth","year":"2020","journal-title":"J Cell Physiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"B48","article-title":"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka","year":"1999","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.10.5211","article-title":"Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity","volume":"163","author":"Shimizu","year":"1999","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/82_2017_58","article-title":"Regulatory T cells: molecular and cellular basis for immunoregulation","volume":"410","author":"Togashi","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01195-4","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Schoemig-Markiefka","year":"2021","journal-title":"Gastric Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10120-019-00999-9","article-title":"Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer","volume":"23","author":"Yamashita","year":"2020","journal-title":"Gastric Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.apsb.2020.11.005","article-title":"Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00396","article-title":"Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer","volume":"9","author":"Oliveira","year":"2019","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210164","article-title":"Immune escape and resistance to immunotherapy in mismatch repair deficient tumors","volume":"14","author":"Mestrallet","year":"2023","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7023","article-title":"Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: A case series","volume":"20","author":"Liu","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.4036","article-title":"Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0219","article-title":"Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer","volume":"11","author":"Kwon","year":"2021","journal-title":"Cancer Discovery"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06487.x","article-title":"High microsatellite instability predicts good prognosis in intestinal-type gastric cancers","volume":"26","author":"Kim","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-012-1652-7","article-title":"Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery","volume":"36","author":"Fang","year":"2012","journal-title":"World J Surg"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2005.08.021","article-title":"Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers","volume":"139","author":"Beghelli","year":"2006","journal-title":"Surgery"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29449","article-title":"The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses","volume":"137","author":"Kim","year":"2015","journal-title":"Int J Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26399","article-title":"Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection","volume":"131","author":"An","year":"2012","journal-title":"Int J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04408-0","article-title":"Predictive biomarkers in gastric cancer","volume":"149","author":"Rocken","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/01.mp.0000076980.73826.c0","article-title":"Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival","volume":"16","author":"Grogg","year":"2003","journal-title":"Mod Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-005-0066-4","article-title":"Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection","volume":"448","author":"Chiaravalli","year":"2006","journal-title":"Virchows Arch"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx213","article-title":"Immune activation and benefit from avelumab in EBV-positive gastric cancer","volume":"110","author":"Panda","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"101657","DOI":"10.1016\/j.tranon.2023.101657","article-title":"Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study","volume":"31","author":"Zhang","year":"2023","journal-title":"Transl Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1938381","DOI":"10.1080\/2162402x.2021.1938381","article-title":"The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Wei","year":"2021","journal-title":"Oncoimmunology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41598-021-81667-w","article-title":"PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms","volume":"11","author":"Nakano","year":"2021","journal-title":"Sci Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2856","article-title":"Update on Epstein-Barr virus and gastric cancer (review)","volume":"46","author":"Shinozaki-Ushiku","year":"2015","journal-title":"Int J Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/cancers11111798","article-title":"Tumor mutational burden and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-0458","article-title":"Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: A meta-regression analysis","volume":"26","author":"Osipov","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0121","article-title":"Association of tumor mutational burden with efficacy of pembrolizumab \u00b1 Chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/cancers14020290","article-title":"Claudins and gastric cancer: an overview","volume":"14","author":"Hashimoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00120-3","article-title":"Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006666","article-title":"TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma","volume":"11","author":"Shi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"21072","DOI":"10.1038\/s41598-021-00626-7","article-title":"Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B100","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12967-023-04845-6","article-title":"MTFR2-dependent mitochondrial fission promotes HCC progression","volume":"22","author":"Zhang","year":"2024","journal-title":"J Transl Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1192434","article-title":"Cuproptosis\/ferroptosis-related gene signature is correlated with immune infiltration and predict the prognosis for patients with breast cancer","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"101784","DOI":"10.1016\/j.tranon.2023.101784","article-title":"Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma","volume":"38","author":"Ding","year":"2023","journal-title":"Transl Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1176647","article-title":"Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejca.2017.07.026","article-title":"Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine","volume":"84","author":"Nebot-Bral","year":"2017","journal-title":"Eur J Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1864","article-title":"Association of gender and parenthood with conference attendance among early career oncologists","volume":"5","author":"Knoll","year":"2019","journal-title":"JAMA Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41588-022-01108-w","article-title":"Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity","volume":"54","author":"Ma","year":"2022","journal-title":"Nat Genet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"15767","DOI":"10.1038\/s41598-019-52414-z","article-title":"Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population","volume":"9","author":"Yao","year":"2019","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","first-page":"193","DOI":"10.21037\/tcr-21-1601","article-title":"Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma","volume":"11","author":"Zhu","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 blockade in solid tumors with defects in polymerase epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov"},{"key":"B111","doi-asserted-by":"publisher","first-page":"15321","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3390\/jcm10102108","article-title":"The emerging role of liquid biopsy in gastric cancer","volume":"10","author":"Lengyel","year":"2021","journal-title":"J Clin Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","article-title":"The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Jin","year":"2020","journal-title":"Mol cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2360","article-title":"Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: A prospective study","volume":"25","author":"Qiao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41571-023-00785-8","article-title":"Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy","volume":"20","author":"Thomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.3390\/cancers14133276","article-title":"An immune signature for risk stratification and therapeutic prediction in helicobacter pylori-infected gastric cancer","volume":"14","author":"Geng","year":"2022","journal-title":"Cancers"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323392","article-title":"Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies","volume":"71","author":"Oster","year":"2022","journal-title":"Gut"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12878","article-title":"Influence of Helicobacter pylori infection on PD-1\/PD-L1 blockade therapy needs more attention","volume":"27","author":"Shi","year":"2022","journal-title":"Helicobacter"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","article-title":"Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1521-4141(199912)29:12<3867::aid-immu3867>3.3.co;2-5","article-title":"Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses","volume":"29","author":"Prigent","year":"1999","journal-title":"Eur J Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01636","article-title":"First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study","volume":"42","author":"Hegewisch-Becker","year":"2024","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open"},{"key":"B129","article-title":"Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis","volume":"8","author":"Cheng","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9743","article-title":"The effects of Tim-3 activation on T-cells in gastric cancer progression","volume":"17","author":"Yu","year":"2019","journal-title":"Oncol Lett"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1954761","DOI":"10.1080\/2162402x.2021.1954761","article-title":"Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry","volume":"10","author":"Park","year":"2021","journal-title":"Oncoimmunology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01607-3","article-title":"TIM3(+) cells in gastric cancer: clinical correlates and association with immune context","volume":"126","author":"Chen","year":"2022","journal-title":"Br J Cancer"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S187219","article-title":"Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03727-y","article-title":"Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma","volume":"148","author":"Kim","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14210","article-title":"Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"39","author":"Shao","year":"2019","journal-title":"Liver Int"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.001","article-title":"Immunomodulatory impact of \u03b1-fetoprotein","volume":"43","author":"Munson","year":"2022","journal-title":"Trends Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12885-024-11999-z","article-title":"Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.08.027","article-title":"Regulation of LSD1 histone demethylase activity by its associated factors","volume":"19","author":"Shi","year":"2005","journal-title":"Mol Cell"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1021\/jm401002r","article-title":"Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration","volume":"56","author":"Zheng","year":"2013","journal-title":"J Med Chem"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00423","article-title":"Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine derivatives as novel LSD1 inhibitors","volume":"8","author":"Li","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.006","article-title":"Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors","volume":"10","author":"Ma","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00919","article-title":"Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective","volume":"63","author":"Dai","year":"2020","journal-title":"J Med Chem"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S186649","article-title":"Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"De Craene","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B145","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-022-01557-1","article-title":"LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer","volume":"21","author":"Shen","year":"2022","journal-title":"Mol Cancer"},{"key":"B146","doi-asserted-by":"publisher","first-page":"115684","DOI":"10.1016\/j.ejmech.2023.115684","article-title":"Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer","volume":"259","author":"Dai","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B147","doi-asserted-by":"publisher","first-page":"111846","DOI":"10.1016\/j.yexcr.2020.111846","article-title":"Lactic acid promotes macrophage polarization through MCT-HIF1\u03b1 signaling in gastric cancer","volume":"388","author":"Zhang","year":"2020","journal-title":"Exp Cell Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1065927","article-title":"Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2008.01.008","article-title":"The functional consequences of alternative promoter use in mammalian genomes","volume":"24","author":"Davuluri","year":"2008","journal-title":"Trends Genet"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2012.05.019","article-title":"First exon length controls active chromatin signatures and transcription","volume":"2","author":"Bieberstein","year":"2012","journal-title":"Cell Rep"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy550","article-title":"Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer","volume":"30","author":"Sundar","year":"2019","journal-title":"Ann Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0538056100","article-title":"Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice","volume":"100","author":"Johnson","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324420","article-title":"Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition","volume":"71","author":"Sundar","year":"2022","journal-title":"Gut"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13829","article-title":"Homologous recombination deficiency: cancer predispositions and treatment implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"key":"B156","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-022-01283-7","article-title":"Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients","volume":"15","author":"Zhou","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.02.011","article-title":"Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma","volume":"153","author":"Morse","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0089","article-title":"The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer","volume":"17","author":"Fan","year":"2020","journal-title":"Cancer Biol Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1599908\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:10:58Z","timestamp":1747195858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1599908\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":158,"alternative-id":["10.3389\/fimmu.2025.1599908"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1599908","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1599908"}}